Novel Concepts Medical

growth-positive

Startup company Novel Concepts Medical has made a major breakthrough in its research of COVID-19. Its plant-based treatment has successfully inhibited the COVID-19 Omicron variant and blocked its connection to human cells. The treatment has shown promising results in stopping the viruss entry to cells and reducing symptoms of long COVID-19. The company is welcoming emergency testing requests from all countries and plans to hold an initial public offering in 2022. The research was conducted in collaboration with the Centre for Microbial Chemical Biology at McMaster University in Canada and the Smart Assays Lab in Israel.

growth-positive

Israeli medical startup Novel Concepts claims to have developed a plant-based COVID-19 treatment that can stop the attachment of the virus, including the Omicron variant, to human cells. The treatment has shown promising results in stopping the progression of the virus and reducing long-COVID symptoms. Novel Concepts is welcoming emergency testing requests from multiple countries and plans to submit the treatment for emergency use authorization. The companys findings can be viewed on its website. The treatment is made of natural compounds that are individually approved for other uses and can be stored at room temperature, making it easier to transport. Novel Concepts plans to hold an IPO in 2022.